Skip to main content
CBD for Epilepsy

Another Study Says CBD Is An Effective Treatment for Severe Form of Childhood Epilepsy

A new study shows cannabidiol (CBD) was found to be an effective long-term therapy for treatment of Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy which causes frequent seizures of different kinds. The disease is difficult to treat, and researchers are seeking new therapies. 

The seizures experienced by LGS patients usually begin between the ages 2 and 6. According to WebMD, children with LGS have learning difficulties and developmental delays such as with sitting, crawling, and walking which can be moderate to severe. Most experience ongoing seizures and some form of learning disability and behavioral problems.

According to the interim analysis of two Phase 3 trials, adding CBD to the treatment regimen can result in a sustained decrease in seizure frequency and improved the overall condition of patients with LGS.

Participants in the trial, which was published by the American Epilepsy Society, received 100mg/mL of CBD in an oral solution for up to 2 years. The initial dose administered was 20mg/kg daily. The dose was titrated down or up (max: 30mg/kg/day) by the investigator. The average dose of CBD administered during the treatment phase was 23mg/kg/day, and the average exposure period for patients included in the study was 36 weeks (range: 3 days, 61 weeks).

The average patient in the study was 16 years old, and 54% of the patients were males. Concomitant prescription drugs patients were taking during the study included clobazam and valproic acid. Prior to randomization, a median of 80 drop seizures were experienced by patients with a total of 168 seizures occurring in a 28-day period.

According to the study's authors, CBD was generally well tolerated and effective. “When analyzed in 12-week intervals over 60 weeks, median monthly drop seizures decreased by 48%–70%, and total seizures decreased by 48%–62%. Approximately 88% of patients/caregivers reported an improvement in overall condition on the S/CGIC at Weeks 24 and 48.”